Real-World data reveals how breast cancer patients fare after initial therapy
NCT ID NCT06975371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study analyzed data from 1,415 patients with HR-positive, HER2-negative metastatic breast cancer in the United States. Researchers looked at what happened after patients progressed on their first-line treatment (endocrine therapy plus a CDK4/6 inhibitor) and started a second-line therapy. The goal was to understand real-world progression-free survival and overall survival using the Flatiron Health Database.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Flatiron Health, Inc
New York, New York, 10013, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which drug first? new study aims to improve breast cancer treatment order
- New combo shows promise for aggressive breast cancer
- New combo therapy aims to slow advanced breast cancer in patients who relapsed
- Blood test could help personalize breast cancer therapy
- New hope for advanced breast cancer: drug combo trial launches